Efectos pleiotrópicos de las estatinas

Results of numerous epidemiologic studies indicate that elevated serum cholesterol, especially the LDL fraction, is a major cause of coronary heart disease (CHD). Epidemiologic and angiographic evidence from primary and secondary prevention studies involving several HMG-CoA reducíase inhibitors (sta...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mennickent C,Sigrid, Bravo D,Marisol, Calvo M,Carlos, Avello L,Marcia
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2008
Materias:	Coronary disease Hydroxymethylglutaryl-CoA reductase inhibitors Intracellular signalingpeptides and proteins
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872008000600014
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872008000600014
record_format	dspace
spelling	oai:scielo:S0034-988720080006000142008-08-27Efectos pleiotrópicos de las estatinasMennickent C,SigridBravo D,MarisolCalvo M,CarlosAvello L,Marcia Coronary disease Hydroxymethylglutaryl-CoA reductase inhibitors Intracellular signalingpeptides and proteins Results of numerous epidemiologic studies indicate that elevated serum cholesterol, especially the LDL fraction, is a major cause of coronary heart disease (CHD). Epidemiologic and angiographic evidence from primary and secondary prevention studies involving several HMG-CoA reducíase inhibitors (statins) indicate that decreasing elevated serum cholesterol concentration (specifically LDL-cholesterol) can reduce the incidence of CHD and/or progression of atherosclerosis and results in a decrease in associated morbidity and mortality. It has been estimated that each 1% reduction in LDL-cholesterol concentration may result in a 1% decrease in the incidence of CHD. Furthermore, an analysis of pooled data from primary and secondary prevention studies found that treatment with a statin for a median duration of 5.4 years was associated with a 31% and 21% reduction in the risk of major coronary events and total mortality, respectively. This paper deals with the pharmacology of statins, specially with the pleiotropic effects ofthese drugsinfo:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.136 n.6 20082008-06-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872008000600014es10.4067/S0034-98872008000600014
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Coronary disease Hydroxymethylglutaryl-CoA reductase inhibitors Intracellular signalingpeptides and proteins
spellingShingle	Coronary disease Hydroxymethylglutaryl-CoA reductase inhibitors Intracellular signalingpeptides and proteins Mennickent C,Sigrid Bravo D,Marisol Calvo M,Carlos Avello L,Marcia Efectos pleiotrópicos de las estatinas
description	Results of numerous epidemiologic studies indicate that elevated serum cholesterol, especially the LDL fraction, is a major cause of coronary heart disease (CHD). Epidemiologic and angiographic evidence from primary and secondary prevention studies involving several HMG-CoA reducíase inhibitors (statins) indicate that decreasing elevated serum cholesterol concentration (specifically LDL-cholesterol) can reduce the incidence of CHD and/or progression of atherosclerosis and results in a decrease in associated morbidity and mortality. It has been estimated that each 1% reduction in LDL-cholesterol concentration may result in a 1% decrease in the incidence of CHD. Furthermore, an analysis of pooled data from primary and secondary prevention studies found that treatment with a statin for a median duration of 5.4 years was associated with a 31% and 21% reduction in the risk of major coronary events and total mortality, respectively. This paper deals with the pharmacology of statins, specially with the pleiotropic effects ofthese drugs
author	Mennickent C,Sigrid Bravo D,Marisol Calvo M,Carlos Avello L,Marcia
author_facet	Mennickent C,Sigrid Bravo D,Marisol Calvo M,Carlos Avello L,Marcia
author_sort	Mennickent C,Sigrid
title	Efectos pleiotrópicos de las estatinas
title_short	Efectos pleiotrópicos de las estatinas
title_full	Efectos pleiotrópicos de las estatinas
title_fullStr	Efectos pleiotrópicos de las estatinas
title_full_unstemmed	Efectos pleiotrópicos de las estatinas
title_sort	efectos pleiotrópicos de las estatinas
publisher	Sociedad Médica de Santiago
publishDate	2008
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872008000600014
work_keys_str_mv	AT mennickentcsigrid efectospleiotropicosdelasestatinas AT bravodmarisol efectospleiotropicosdelasestatinas AT calvomcarlos efectospleiotropicosdelasestatinas AT avellolmarcia efectospleiotropicosdelasestatinas
_version_	1718436385325580288

Efectos pleiotrópicos de las estatinas

Ejemplares similares